

Christophe Massard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/241514/publications.pdf>

Version: 2024-02-01

74
papers

7,238
citations

172457

29
h-index

58581

82
g-index

90
all docs

90
docs citations

90
times ranked

11429
citing authors

#	ARTICLE	IF	CITATIONS
1	Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox. <i>European Journal of Cancer</i> , 2022, 162, 128-129.	2.8	2
2	Re: Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. <i>European Urology</i> , 2022, 81, 545-546.	1.9	1
3	Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials. <i>European Journal of Cancer</i> , 2022, 163, 98-107.	2.8	1
4	Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. <i>European Urology</i> , 2022, 82, 22-30.	1.9	34
5	Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. <i>European Journal of Cancer</i> , 2022, 167, 42-53.	2.8	2
6	Report of the First International Symposium on NUT Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2493-2505.	7.0	23
7	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	2.1	7
8	Patterns of progression in patients treated for immuno-oncology antibodies combination. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 221-232.	4.2	12
9	Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2021, 39, 193-201.	2.6	10
10	Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies. <i>Translational Oncology</i> , 2021, 14, 100984.	3.7	9
11	A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 1089-1098.	2.6	19
12	Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 709-718.	2.1	5
13	PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. <i>Cancer Research</i> , 2021, 81, 2888-2902.	0.9	66
14	Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years. <i>European Journal of Cancer</i> , 2021, 156, 217-221.	2.8	1
15	The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. <i>European Journal of Cancer</i> , 2021, 158, 217-224.	2.8	35
16	Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon. <i>EXCLI Journal</i> , 2021, 20, 819-827.	0.7	2
17	Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. <i>Investigational New Drugs</i> , 2020, 38, 402-409.	2.6	43
18	An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. <i>European Urology Oncology</i> , 2020, 3, 498-508.	5.4	27

#	ARTICLE	IF	CITATIONS
19	Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. <i>European Journal of Cancer</i> , 2020, 129, 117-122.	2.8	12
20	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. <i>Cancer Medicine</i> , 2020, 9, 2643-2652.	2.8	21
21	Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 444-451.	1.9	6
22	Exploring the optimal use of alectinib. <i>Lancet Respiratory Medicine</i> , 2019, 7, 373-374.	10.7	2
23	<p>>Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential</p>>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2505-2512.	2.0	17
24	First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1057-1063.	2.3	16
25	Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-10.	2.1	6
26	Long-Term Survival in Patients Responding to Anti-“PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019, 25, 946-956.	7.0	96
27	Durvalumab in urothelial cancers. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 311-318.	2.4	8
28	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. <i>European Journal of Cancer</i> , 2018, 92, 1-10.	2.8	14
29	First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1536-1545.	7.0	76
30	Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 3007-3014.	1.6	184
31	Hyperprogressive disease: recognizing a novel pattern to improve patient management. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 748-762.	27.6	304
32	Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours. <i>European Journal of Cancer</i> , 2018, 103, 88-97.	2.8	22
33	Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?. <i>European Journal of Cancer</i> , 2018, 103, 108-119.	2.8	18
34	A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. <i>Lancet Oncology</i> , 2018, 19, 1180-1191.	10.7	811
35	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018, 9, 9741-9750.	1.8	12
36	Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. <i>European Journal of Cancer</i> , 2017, 79, 185-192.	2.8	24

#	ARTICLE	IF	CITATIONS
37	The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial. <i>Genetics in Medicine</i> , 2017, 19, 683-690.	2.4	24
38	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. <i>Cancer Discovery</i> , 2017, 7, 586-595.	9.4	554
39	Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2017, 76, 36-44.	2.8	64
40	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). <i>European Journal of Cancer</i> , 2017, 84, 212-218.	2.8	132
41	First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices. <i>Bulletin Du Cancer</i> , 2017, 104, 552-558.	1.6	2
42	RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. <i>European Journal of Cancer</i> , 2017, 83, 185-193.	2.8	19
43	Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. <i>JAMA Oncology</i> , 2017, 3, e172411.	7.1	750
44	Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1081-e1088.	1.9	6
45	Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. , 2017, 5, 31.		45
46	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. <i>Clinical Cancer Research</i> , 2017, 23, 1920-1928.	7.0	960
47	A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. <i>PLoS ONE</i> , 2016, 11, e0154895.	2.5	10
48	Nonfamilial Chronic Serum Alpha-Fetoprotein Increase in a Patient With Clinical Stage IâSeminoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e91-e93.	1.9	1
49	Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. <i>European Journal of Cancer</i> , 2016, 61, 44-51.	2.8	40
50	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations. <i>Cancer Research</i> , 2016, 76, 5954-5961.	0.9	16
51	Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. <i>European Journal of Cancer</i> , 2016, 69, 151-157.	2.8	31
52	Safety and Efficacy of Durvalumab (MEDI4736), an Antiâ€“Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3119-3125.	1.6	755
53	Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. <i>Clinical Cancer Research</i> , 2016, 22, 2960-2968.	7.0	103
54	Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01). <i>European Journal of Cancer</i> , 2016, 59, 79-89.	2.8	36

#	ARTICLE	IF	CITATIONS
55	Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. Insights Into Imaging, 2016, 7, 205-214.	3.4	45
56	Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. Journal of Clinical Oncology, 2016, 34, 833-842.	1.6	517
57	Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: a report from the PETRUS prospective study. Oncotarget, 2016, 7, 55069-55082.	1.8	33
58	Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma. Cancer Biomarkers, 2015, 15, 151-156.	1.7	12
59	Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. European Journal of Cancer, 2015, 51, 1946-1952.	2.8	63
60	Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 202.e9-202.e17.	1.6	31
61	Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?. European Urology, 2015, 68, 802-804.	1.9	0
62	High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. European Journal of Cancer, 2015, 51, 2570-2577.	2.8	91
63	Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. European Urology, 2015, 68, 154-160.	1.9	53
64	Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. European Urology, 2015, 68, 228-235.	1.9	144
65	Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials. Clinical Cancer Research, 2014, 20, 246-252.	7.0	144
66	One Size Does Not Fit All: Can We Choose the Best Sequence of Treatment in Asymptomatic Castration-resistant Prostate Cancer Patients?. European Urology, 2014, 66, 653-654.	1.9	1
67	Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncology, The, 2014, 15, 975-985.	10.7	172
68	Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours. European Journal of Cancer, 2014, 50, 1284-1290.	2.8	26
69	Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. European Journal of Cancer, 2014, 50, 1602-1609.	2.8	50
70	Evaluation of circulating tumor cells (CTCs) enumeration and 18F-Choline positron emission tomography/computed tomography (FCH PET/CT) as early efficacy response biomarkers in metastatic castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate.. Journal of Clinical Oncology, 2012, 30, 63-63.	1.6	2
71	Carcinomas of an unknown primary origin—diagnosis and treatment. Nature Reviews Clinical Oncology, 2011, 8, 701-710.	27.6	120
72	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. Clinical Cancer Research, 2011, 17, 5188-5196.	7.0	29

#	ARTICLE	IF	CITATIONS
73	Targeting Continued Androgen Receptor Signaling in Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3876-3883.	7.0	160
74	Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 78-79.	2.9	1